Cubist Systematic Strategies’s Lineage Cell Therapeutics LCTX Stock Holding History

Cubist Systematic Strategies’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$63.4K	Sell	37,485 -397,774	-91%	-$471K	﹤0.01%	2829
2025 Q2	$395K	Buy	+435,259	New	+$258K	﹤0.01%	2341
2023 Q2	–	Sell	-30,155	Closed	-$45.2K	–	3946
2023 Q1	$45.2K	Buy	30,155 +5,678	+23%	+$7.92K	﹤0.01%	3581
2022 Q4	$28.6K	Sell	24,477 -13,634	-36%	-$17.2K	﹤0.01%	3967
2022 Q3	$43K	Sell	38,111 -50,663	-57%	-$74.4K	﹤0.01%	4148
2022 Q2	$140K	Buy	+88,774	New	+$117K	﹤0.01%	3846
2021 Q3	–	Sell	-47,500	Closed	-$135K	–	3068
2021 Q2	$135K	Sell	47,500 -96,200	-67%	-$249K	﹤0.01%	2671
2021 Q1	$338K	Buy	+143,700	New	+$345K	﹤0.01%	2187
2020 Q4	–	Sell	-91,806	Closed	-$86K	–	2640
2020 Q3	$86K	Buy	+91,806	New	+$81.1K	﹤0.01%	2306

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return

Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

DIG

Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Cubist Systematic Strategies's LCTX Position: Q3 2025 in Review

Cubist Systematic Strategies reduced its Lineage Cell Therapeutics (LCTX) stake by 91% in Q3 2025, selling an estimated $471K and leaving 37,485 shares worth $63.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2829.

Cubist Systematic Strategies first reported a position in LCTX in Q3 2020 and has held it in 9 quarters since. The position peaked at $395K in Q2 2025. 112 funds tracked by Wall St. Rank hold LCTX as of Q3 2025.

Cubist Systematic Strategies held 37,485 shares of Lineage Cell Therapeutics worth $63.4K as of Q3 2025.
Cubist Systematic Strategies sold 397,774 Lineage Cell Therapeutics shares in Q3 2025, an estimated $471K.
Lineage Cell Therapeutics made up ﹤0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #2829 holding.
Cubist Systematic Strategies first reported a position in Lineage Cell Therapeutics in Q3 2020 and has held it in 9 quarters since.
Cubist Systematic Strategies's Lineage Cell Therapeutics position peaked at $395K in Q2 2025.
112 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.